Tryptophan metabolism in breast cancers: Molecular imaging and immunohistochemistry studies

Nuclear Medicine and Biology

Volumn 39, Issue 7, 2012, Pages 926-932

  Juhász, Csaba ^a,b,c   Nahleh, Zeina ^c,e   Zitron, Ian ^b,c   Chugani, Diane C ^a,b,d   Janabi, Majid Z ^a,d   Bandyopadhyay, Sudeshna ^b,c   Ali Fehmi, Rouba ^b,c   Mangner, Thomas J ^a,d   Chakraborty, Pulak K ^a,d   Mittal, Sandeep ^b,c   Muzik, Otto ^a,b,d  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Breast cancer; Immunohistochemistry; Kynurenine; Positron emission tomography; Serotonin; Tryptophan

Indexed keywords

ALPHA METHYL LEVO TRYPTOPHAN C 11; AMINO ACID; AMINO ACID TRANSPORTER; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; PROTEIN LAT1; PROTEIN TPH1; RADIOPHARMACEUTICAL AGENT; SEROTONIN; TRYPTOPHAN HYDROXYLASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER STAGING; CARCINOSARCOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOLECULAR DYNAMICS; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRYPTOPHAN METABOLISM;

ADULT; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KINETICS; LARGE NEUTRAL AMINO ACID-TRANSPORTER 1; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; TRYPTOPHAN; TRYPTOPHAN HYDROXYLASE;

EID: 84866051674     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.01.010     Document Type: Article

References (37)

1. Uyttenhove C., Pilotte L., Theate I., Stroobant V., Colau D., Parmentier N., et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003, 9:1269-1274.
2. Munn D.H., Mellor A.L. IDO and tolerance to tumors. Trends Mol Med 2004, 10:15-18.
3. Travers M.T., Gow I.F., Barber M.C., Thomson J., Shennan D.B. Indoleamine 2,3-dioxygenase activity and l-tryptophan transport in human breast cancer cells. Biochim Biophys Acta 2004, 1661:106-112.
4. Sakurai K., Amano S., Enomoto K., Kashio M., Saito Y., Sakamoto A., et al. Study of indoleamine 2,3-dioxygenase expression in patients with breast cancer. Gan To Kagaku Ryoho 2005, 32:1546-1549.
5. Jacquemier J., Bertucci F., Finetti P., Esterni B., Charafe-Jauffret E., Thibult M.L., et al. High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma. Int J Cancer 2012, 130:96-104.
6. Pai V.P., Marshall A.M., Hernandez L.L., Buckley A.R., Horseman N.D. Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival. Breast Cancer Res 2009, 11:R81.
7. Fuchs B.C., Bode B.P. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime?. Semin Cancer Biol 2005, 15:254-266.
8. Shennan D.B., Thomson J., Barber M.C., Travers M.T. Functional and molecular characteristics of system L in human breast cancer cells. Biochim Biophys Acta 2003, 1611:81-90.
9. Kaira K., Oriuchi N., Imai H., Shimizu K., Yanagitani N., Sunaga N., Hisada T., et al. L-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. Cancer Sci 2008, 99:2380-2386.
10. Esseghir S., Reis-Filho J.S., Kennedy A., James M., O'Hare M.J., Jeffrey R., et al. Identification of transmembrane proteins as potential prognostic markers and therapeutic targets in breast cancer by a screen for signal sequence encoding transcripts. J Pathol 2006, 210:420-430.
11. Ring B.Z., Seitz R.S., Beck R., Shasteen W.J., Tarr S.M., Cheang M.C.U., et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24:3039-3047.
12. Shennan D.B., Thomson J. Inhibition of system L (LAT1/CD98hc) reduces the growth of cultured human breast cancer cells. Oncol Rep 2008, 20:885-889.
13. Kaji M., Kabir-Salmani M., Anzai N., Jin C.J., Akimoto Y., Horita A., et al. Properties of L-type amino acid transporter 1 in epidermal ovarian cancer. Int J Gynecol Cancer 2010, 20:329-336.
14. Jia L., Schweikart K., Tomaszewski J., Page J.G., Noker P.E., Buhrow S.A., et al. Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. Food Chem Toxicol 2008, 46:203-211.
15. Liu Q., Yang Q., Sun W., Vogel P., Heydorn W., Yu X.Q., et al. Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract. J Pharmacol Exp Ther 2008, 325:47-55.
16. Imai H., Kaira K., Oriuchi N., Shimizu K., Tominaga H., Yanagitani N., et al. Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer. Anticancer Res 2010, 30:4819-4828.
17. Yi Y.M., Zhang G., Zeng J., Huang S.C., Li L.L., Fang R., et al. A new tumor vaccine: FAPτ-MT elicits effective antitumor response by targeting indolamine 2,3-dioxygenase in antigen presenting cells. Cancer Biol Ther 2011, 11:866-873.
18. 14C]methyl-l-tryptophan (alpha-MTrp) and its correlation with regional serotonin synthesis, tryptophan incorporation into proteins, and permeability surface area products of tryptophan and alpha-MTrp. Neurochem Res 2000, 25:1537-1546.
19. Tohyama Y., Takahashi S., Merid M.F., Watanabe A., Diksic M. The inhibition of tryptophan hydroxylase, not protein synthesis, reduces the brain trapping of alpha-methyl-l-tryptophan: an autoradiographic study. Neurochem Int 2002, 40:603-610.
20. Diksic M. Alpha-methyl tryptophan as a tracer for in vivo studies of brain serotonin system, from autoradiography to positron emission tomography. J Chem Neuroanat 1992, 5:349-354.
21. Shimizu T., Nomiyama S., Hirata F., Hayaishi O. Indoleamine 2,3-dioxygenase. Purification and some properties. J Biol Chem 1978, 253:4700-4706.
22. Chugani D.C., Muzik O. α[C-11]methyl-l-tryptophan PET maps brain serotonin[U+F02D] synthesis and kynurenine pathway metabolism. J Cereb Blood Flow Metab 2000, 20:2-9.
23. Batista C.E., Juhász C., Muzik O., Kupsky W.J., Barger G., Chugani H.T., et al. Imaging correlates of differential expression of indoleamine 2,3-dioxygenase in human brain tumors. Mol Imaging Biol 2009, 11:460-466.
24. Juhász C., Muzik O., Lu X., Jahania M.S., Soubani A.O., Khalaf M., et al. Quantification of tryptophan transport and metabolism in lung tumors using PET. J Nucl Med 2009, 50:356-363.
25. 11C]methyl-l-tryptophan. Nucl Med Biol 1996, 23:1005-1008.
26. Muzik O., Behrendt D.B., Mangner T.J., Chugani H.T. Design of a protocol for quantitative brain FDG studies with PET not requiring invasive blood sampling [abstract]. J Nucl Med 1994, 35:104.
27. Suhonen-Polvi H., Ruotsalainen U., Kinnala A., Bergman J., Haaparanta M., Teras M., et al. FDG-PET in early infancy: simplified quantification methods to measure cerebral glucose utilization. J Nucl Med 1995, 36:1249-1254.
28. Seymour R.L., Ganapathy V., Mellor A.L., Munn D.H. A high-affinity, tryptophan-selective amino acid transport system in human macrophages. J Leukoc Biol 2006, 80:1320-1327.
29. Silk J.D., Lakhal S., Laynes R., Vallius L., Karydis I., Marcea C., et al. IDO induces expression of a novel tryptophan transporter in mouse and human tumor cells. J Immunol 2011, 187:1617-1625.
30. Belsley D. Conditioning diagnostics: collinearity and weak data in regression 1991, Wiley & Sons, New York.
31. 11C]methyl-l-tryptophan in human brain tumors. J Cereb Blood Flow Metab 2006, 26:345-357.
32. Godin-Ethier J., Pelletier S., Hanafi L.A., Gannon P.O., Forget M.A., Routy J.P., et al. Human activated T lymphocytes modulate IDO expression in tumors through Th1/Th2 balance. J Immunol 2009, 183:7752-7760.
33. Lyon D.E., Walter J.M., Starkweather A.R., Schubert C.M., McCain N.L. Tryptophan degradation in women with breast cancer: a pilot study. BMC Res Notes 2011, 4:156.
34. Kaper T., Looger L.L., Takanaga H., Platten M., Steinman L., Frommer W.B. Nanosensor detection of an immunoregulatory tryptophan influx/kynurenine efflux cycle. PLoS Biol 2007, 5:e257.
35. Serbecic N., Lahdou I., Scheuerle A., Höftberger R., Aboul-Enein F. Function of the tryptophan metabolite, l-kynurenine, in human corneal endothelial cells. Mol Vis 2009, 15:1312-1324.
36. Zamanakou M., Germenis A.E., Karanikas V. Tumor immune escape mediated by indoleamine 2,3-dioxygenase. Immunol Lett 2007, 111:69-75.
37. Liu X., Newton R.C., Friedman S.M., Scherle P.A. Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy. Curr Cancer Drug Targets 2009, 9:938-952.